<?xml version="1.0" encoding="utf-8"?><svg:svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:svg="http://www.w3.org/2000/svg" version="1.1" width="595.22px" height="842px" preserveAspectRatio="none" viewBox="0 0 595.22 842"><svg:defs><svg:clipPath id="--clippath0" transform=""><svg:path d="M 0 0 L 595.22 0 L 595.22 842 L 0 842 Z" stroke-miterlimit="0" stroke-linecap="" stroke-linejoin="" stroke-width="1px" stroke-dasharray="" stroke-dashoffset="0px" fill="none" clip-rule="nonzero"></svg:path></svg:clipPath><svg:style type="text/css">@font-face { font-family: "g_d0_f1";; src: url(data:font/woff;base64,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); }  @font-face { font-family: "g_d0_f2";; src: url(data:font/woff;base64,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); }  @font-face { font-family: "g_d0_f3";; src: url(data:font/woff;base64,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); }  @font-face { font-family: "g_d0_f4";; src: url(data:font/woff;base64,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); }  @font-face { font-family: "g_d0_f5";; src: url(data:font/woff;base64,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); } </svg:style></svg:defs><svg:g transform="matrix(1 0 0 -1 0 842)"><svg:g transform=""><svg:path d="M 0 0 L 595.22 0 L 595.22 842 L 0 842 Z" stroke-miterlimit="0" stroke-linecap="" stroke-linejoin="" stroke-width="1px" stroke-dasharray="" stroke-dashoffset="0px" fill="none" clip-rule="nonzero"></svg:path></svg:g><svg:g clip-path="url(#clippath0)"><svg:g transform=""><svg:text transform="matrix(11 0 0 11 272.801 779.4779) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.258" x="0 0.593 1.113 1.295 1.8 2.307 2.812 3.329 3.83 4.18 4.702 5.224 5.52 6.042 6.38 7.077 7.599 7.937 8.454 8.955 9.305 9.791 10.141 10.656 11.142 11.576 11.758 12.28 12.802 13.116 13.638 13.988 14.51 15.032 15.382 15.883 16.065 16.379 16.899 17.385 17.819 18.001 18.518 19.04 19.562 20.063 20.413 20.935 21.436 21.951 22.473 22.907 23.089 23.575 23.745 24.267" font-family="g_d0_f1" font-size="1px" fill="rgb(43,46,52)">Cuidados enfermeros a paciente en situaciones especiales</svg:tspan></svg:text><svg:text transform="matrix(7.5 0 0 7.5 537.115 52.9521) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.25" x="0 0.556 1.057" font-family="g_d0_f2" font-size="1px" fill="rgb(43,46,52)">501</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 70.8661 756.5768) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.25" x="0 0.722 1.333 1.666 1.944 2.444 3.055 3.611 4 4.611 5.222 5.722 6 6.944 7.555 8.166 8.777 9.277 9.555 10.166 10.777 11.333 11.611 12.167 12.667 12.945 13.445 14.056 14.667 14.945 15.501 16.001 16.501 16.779 17.39 18.001 18.279 18.835 19.446 19.779 20.057 20.668 21.224 21.835 22.446 22.724 23.28 23.78 24.058 24.558" font-family="g_d0_f2" font-size="1px" fill="rgb(64,198,192)">Anticuerpos monoclonales con acción antineoplásica</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 70.8661 734.838199) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(255,127,125)"></svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 76.32 734.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.339 0.95 1.394 1.838 2.227 2.671 2.893 3.337 3.726 4.004 4.282 4.726 5.004 5.448 5.892 6.114 6.558 6.78 7.224 7.668 7.89 8.334 8.723 9.112 9.334 9.778 10.222 10.444 10.888 11.332 11.61 11.832 12.276 12.72 13.164 13.608 13.83 14.274 14.663 14.885 15.274 15.718 15.94" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)"> Nueva estrategia de acción antineoplásica. </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 70.8661 723.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(255,127,125)"></svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 76.32 723.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.339 0.839 1.283 1.505 1.949 2.393 3.06 3.282 3.726 3.948 4.337 4.615 4.893 5.337 5.781 6.003 6.447 6.891 7.169 7.391 7.78 8.002 8.446 8.668 8.89 9.334 9.612 9.89 10.334 10.723 11.167 11.611 12.055 12.444 12.888 13.11 13.332 13.776 14.165 14.609 14.998 15.22 15.664 16.108 16.552 16.941 17.163 17.607 17.829 18.273 18.551 18.829 19.273 19.662 19.884 20.328 20.772 21.05 21.272 21.716 22.16 22.604 23.048 23.27 23.714 24.103 24.325 24.714 25.158 25.547" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)"> Se administran por vía intravenosa, asociados a otros antineoplásicos.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 70.8661 712.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(255,127,125)"></svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 76.32 712.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)"> </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 712.802) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.225" x="0 0.606 0.823 1.318 2.035 2.308 2.803 3.187 3.682 4.399 4.894" font-family="g_d0_f4" font-size="1px" fill="rgb(43,46,52)">Alemtuzumab</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 127.871099 712.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">:</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 701.8382) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.945 1.334 1.556 1.945 2.167 2.556 2.778 3.222 3.666 3.888 4.11 4.332 4.776 5.054 5.498 5.887 6.109 6.387 6.831 7.22 7.442 8.109 8.553 8.997 9.219 9.663 10.107 10.385 10.829 11.051 11.718 12.162 12.551 12.995 13.439 13.661 14.05 14.717 15.161 15.55 15.772 16.216 16.66 16.882 17.271 17.493 17.771 18.215 18.493 18.937 19.326 19.548 19.937 20.159 20.603 21.047 21.491 21.713" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Lisis de linfocitos mediante mecanismos de citotoxicidad. </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 690.8384) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.945 1.167 1.611 2.055 2.277 2.666 3.11 3.499 3.721 4.165 4.609 5.053 5.442 5.664 5.886 6.33 6.774 7.052 7.496 7.774 8.441 8.885 9.329 9.773 10.217 10.661 11.05 11.272 11.939 12.383 12.605 12.827 13.271 13.715 14.159 14.548 14.77 14.992 15.214 15.658 15.936 16.38 16.602 17.046 17.49 17.879 18.101 18.49 18.934 19.601 20.045 20.267 20.489 20.933 21.155 21.377 21.821 22.265 22.654 23.098 23.765 23.987 24.431 24.653 24.875 25.097 25.541 25.819 26.263 26.652 26.874 27.152 27.374 27.763 28.207 28.429 28.818 29.096 29.54 29.984 30.206 30.595 31.039" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Indicaciones: enfermedades malignas linfoides como la leucemia linfocítica crónica.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 679.8386) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.9448 1.3888 1.6668 2.1108 2.4998 2.7778 3.2218 3.6108 3.8496 4.2936 4.7376 5.1266 5.5706 5.8486 6.2376 6.6816 7.0706 7.2926 7.5314 8.1984 8.4204 8.8644 9.0864 9.5304 9.9744 10.4184 10.8624 11.1404 11.5844 11.9734 12.1954 12.6394 13.0834 13.3054 13.5442 13.7662 14.2102 14.4882 14.9322 15.3212 15.7102 15.9322 16.3762 16.8202 17.0422 17.281 17.725 17.947 18.391 18.835 19.113 19.557 20.001 20.39 20.612 21.056 21.5 21.722 21.9608 22.1828 22.4046 22.8486 23.2926 23.5706 24.0146 24.2366 24.4754 24.9194 25.3084 25.6974 26.1414 26.3634 26.8074 27.0854 27.3634 27.5854 28.0294 28.4184 28.6404 28.8792 29.3232 29.6012 30.0452 30.4892 30.8782 31.3222 31.7662 32.1552 32.5992 33.0432 33.4322 34.0992 34.5432 34.7652 35.004 35.282 35.504 35.948 36.17 36.614 37.058 37.391 37.613 37.8518 38.2958 38.7398 39.1838 39.5728 40.0168 40.4608 40.8498 41.0718 41.3106 41.7546 42.1436 42.4216 42.8656 43.3096 43.5316 43.9756 44.1976 44.4364 44.8254 45.2694 45.5474" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Efectos adversos: mielodepresión, infección, hipotensión, ﬁ ebre, escalofríos, broncoespasmo, rigidez, náuseas, astenia, cefa</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 493.281008 679.8386) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.222 0.666 1.11 1.332 1.5708 2.0148 2.2928 2.7368 3.1808" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">lea, erup-</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 87.874205 668.838799) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.389 0.611 1.055 1.499 1.721 1.943 2.387 2.665 2.943 3.165 3.554 3.998 4.276 4.498 4.942 5.164 5.553 5.775 6.219 6.497 6.941 7.219 7.441 7.719 8.163" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">ción, urticaria y prurito.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 70.8661 646.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(255,127,125)"></svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 76.32 646.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)"> </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 646.802) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.225" x="0 0.606 1.101 1.54 2.035 2.53 2.747 3.131 3.626 4.343 4.838" font-family="g_d0_f4" font-size="1px" fill="rgb(43,46,52)">Bevacizumab</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 127.367102 646.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">:</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 635.8382) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.945 1.167 1.611 2.055 2.277 2.666 3.11 3.499 3.721 4.165 4.609 5.053 5.442 5.664 5.886 6.275 6.719 7.163 7.552 7.996 8.274 8.496 8.885 9.329 9.551 9.995 10.273 10.551 10.995 11.384 11.662 12.106 12.328 12.55 13.217 13.661 13.939 14.383 14.772 15.05 15.494 15.772 15.994 16.383 16.827 17.049" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Indicaciones: cáncer colorrectal metastático. </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 624.8384) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.945 1.389 1.667 2.111 2.5 2.778 3.222 3.611 3.833 4.277 4.721 5.11 5.554 5.832 6.221 6.665 7.054 7.276 7.498 7.776 8.22 8.664 9.053 9.442 9.664 10.108 10.552 10.996 11.385 11.607 12.051 12.495 12.717 13.161 13.383 13.827 14.271 14.549 14.938 15.382 15.826 16.215 16.437 16.881 17.103 17.325 17.547 17.991 18.435 18.879 19.101 19.323 19.767 19.989 20.433 20.877 21.155 21.433 21.877 22.321 22.71 22.932 23.376 23.82 24.042 24.264 24.708 24.986 25.43 25.708 26.152 26.374 26.818 27.262 27.54 27.762 28.206 28.428 28.817 29.039 29.483 29.927 30.594 31.038 31.316 31.594 32.038 32.482 32.704 33.148 33.537 33.759" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Efectos adversos: reacciones de hipersensibilidad, hipertensión, proteinuria y hemorragias. </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 70.8661 602.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(255,127,125)"></svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 76.32 602.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)"> </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 602.802) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.225" x="0 0.551 1.046 1.319 1.814 2.253 2.47 3.187 3.682" font-family="g_d0_f4" font-size="1px" fill="rgb(43,46,52)">Cetuximab</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 116.9631 602.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">:</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 591.8382) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.945 1.167 1.611 2.055 2.277 2.666 3.11 3.499 3.721 4.165 4.609 5.053 5.442 5.664 5.886 6.275 6.719 7.163 7.552 7.996 8.274 8.496 8.885 9.329 9.551 9.995 10.273 10.551 10.995 11.384 11.662 12.106 12.328 12.55 13.217 13.661 13.939 14.383 14.772 15.05 15.494 15.772 15.994 16.383 16.827 17.049 17.438 17.66 18.104 18.548 18.77 19.159 19.603 20.047 20.436 20.88 21.158 21.38 21.824 22.268 22.49 22.879 23.323 23.767 24.211 24.544 24.988 25.21 25.599 25.821 26.21 26.654 27.098 27.32 27.542 27.986" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Indicaciones: cáncer colorrectal metastático y en cáncer de cabeza y cuello.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 580.8384) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.9449 1.3889 1.6669 2.1109 2.4999 2.7779 3.2219 3.6109 3.7938 4.2378 4.6818 5.0708 5.5148 5.7928 6.1818 6.6258 7.0148 7.2368 7.4197 7.8637 8.0857 8.3637 8.5857 8.9747 9.1967 9.4187 9.8627 10.2517 10.4346 10.8786 11.3226 11.5055 11.9495 12.1715 12.5605 12.9495 13.3935 13.6715 14.1155 14.3375 14.6155 14.7984 15.2424 15.6864 15.8693 16.0913 16.5353 16.9243 17.1072 17.5512 17.9952 18.2172 18.4001 18.6221 18.9001 19.1221 19.5661 20.0101 20.2881 20.7321 21.1211 21.5651 22.0091 22.192 22.414 22.858 23.302 23.58 23.802 24.246 24.69 25.134 25.578 25.8 26.244 26.633 26.855 27.244 27.688 27.8709 28.3149 28.7589 29.0369 29.2589 29.6479 30.0919 30.5359 30.9799 31.1628 31.6068 32.0508 32.2337 32.4557 32.8997 33.0826 33.4716 33.9156 34.5826 35.0266 35.3046 35.7486 36.0266 36.4706 36.8596 37.0816 37.5256 37.9696 38.1916 38.3745 38.7635 39.2075 39.6515 39.8344 40.2784 40.5004 40.6833 41.1273 41.5713 42.0153 42.1982 42.5872 43.0312 43.2141 43.6031 44.0471" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Efectos adversos: difíciles de discernir de los del irinotecán (antineoplásico derivado de la camptotecina) con el que se sue</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 479.780115 580.8384) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.222 0.666 0.8489 1.2929 1.7369 2.4039 2.6259 3.0699 3.2919 3.6809 3.9589 4.2369 4.6809 4.9589" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">le administrar </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 87.874205 569.838599) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.444 0.888 1.11 1.388 1.832 2.11 2.777 3.221 3.443 3.832 4.276 4.72 5.109 5.553 6.22 6.442 6.72 7.164 7.608 7.886 8.33 8.552 8.774 9.163 9.385 9.829 10.273 10.551 10.995 11.217 11.439 11.883 12.272 12.661 13.105 13.327 13.771 14.049 14.327 14.549 14.993 15.382 15.604 15.826 16.27 16.659 16.937 17.381 17.825 18.047 18.491 18.713 18.935 19.379 19.601 19.99 20.434 20.878 21.322 21.544 21.766 22.21 22.654 22.876 23.32 23.598 23.82 24.264 24.708 25.152 25.596 26.263 26.485 26.929 27.373 27.595 27.817 28.039 28.428 28.872 29.316 29.538 29.982 30.426 30.704 30.926 31.315 31.537 31.815 32.037 32.426 32.648 33.037 33.259 33.537 33.981 34.425 34.814 35.203 35.425 35.869 36.313 36.757 37.146 37.368 37.812 38.256 38.478 38.922 39.144 39.588 40.032 40.31 40.699 41.143 41.587 41.976 42.198 42.642 42.864 43.086 43.308 43.752 44.196 44.64" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">de forma concomitante. Fiebre, escalofríos, astenia, disnea, dolor abdominal, conjuntivitis y reacciones de hipersensibilidad.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 70.8661 547.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(255,127,125)"></svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 76.32 547.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)"> </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 547.802) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.225" x="0 0.551 0.768 1.041 1.536 1.975 2.192 2.909 3.404" font-family="g_d0_f4" font-size="1px" fill="rgb(43,46,52)">Rituximab</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 114.461099 547.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">:</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 536.8382) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.945 1.167 1.611 2.055 2.277 2.666 3.11 3.499 3.721 4.165 4.609 5.053 5.442 5.664 5.886 6.108 6.33 6.774 7.052 7.496 8.163 8.607 8.829 9.273 9.717 9.939 10.495 10.939 11.383 11.827 12.216 12.438 12.882 13.104 13.382 13.826 14.048 14.27 14.659 15.103 15.325 15.769 16.047 16.269 16.713 17.157 17.379 17.768 18.212 18.434 18.878 19.1 19.544 19.933 20.155 20.655 20.877 21.377 21.933 22.377 22.821 23.265 23.487 23.931 24.375 24.597 24.875 25.319 25.708 26.152 26.374 26.818 27.262 27.484 27.762 28.04 28.484 28.873 29.095 29.539 29.983 30.205 30.872 31.094 31.538 31.816 32.26 32.538 32.982 33.426 33.648 34.092" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Indicaciones: linfoma no Hodgkin folicular de células B CD20+ en recaída tras quimioterapia.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 525.8384) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.9452 1.3892 1.6672 2.1112 2.5002 2.7782 3.2222 3.6112 3.8174 4.2614 4.7054 5.0944 5.5384 5.8164 6.2054 6.6494 7.0384 7.2604 7.4666 7.6886 7.9108 8.3548 8.7988 9.0768 9.5208 9.7428 9.949 10.393 10.782 11.171 11.615 11.837 12.281 12.559 12.837 13.059 13.503 13.892 14.114 14.3202 14.5982 15.0422 15.4862 15.8752 16.2642 16.4862 16.9302 17.3742 17.8182 18.2072 18.4134 18.8574 19.3014 19.5076 19.9516 20.1736 20.6176 21.0616 21.3396 21.7286 22.1726 22.6166 23.0056 23.2276 23.6716 23.8936 24.1156 24.3376 24.7816 25.2256 25.6696 25.8916 26.0978 26.5418 26.7638 27.0418 27.4858 27.7638 28.2078 28.5968 28.8188 29.2628 29.7068 30.1508 30.5398 30.746 31.19 31.634 32.023 32.301 32.579 33.023 33.245 33.689 33.967 34.411 34.8 35.078 35.3 35.744 36.188 36.41 36.854 37.243 37.465 37.6712 38.1152 38.3372 38.7812 39.2252 39.5032 39.9472 40.3912 40.7802 41.0022 41.4462 41.8902 42.1122 42.3184 42.7624 43.0404 43.3184 43.5404 43.8184 44.4854" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Efectos adversos: ﬁ ebre, escalofríos, reacciones de hipersensibilidad, alteraciones gastrointestinales, hipotensión, arritmi</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 481.719614 525.8384) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.444 0.833 1.055 1.2612 1.7052 2.1492 2.3712 2.8152 3.0932 3.2994 3.7434 4.0214 4.4654" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">as, dolor pre-</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 87.873312 514.838599) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.389 0.833 1.111 1.555 1.777 2.221 2.443 2.665 3.054 3.276 3.943 4.165 4.609 4.831 5.275 5.664 6.108 6.552 6.83 7.274 7.663 7.885 8.329 8.773" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">cordial y mielosupresión.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 70.8661 492.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(255,127,125)"></svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 76.32 492.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)"> </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 492.802) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.225" x="0 0.273 0.768 1.096 1.313 1.586 2.081 2.798 3.293 4.01 4.505 5 5.217 5.49 5.707 6.202 6.641 7.136 7.409 7.904 8.399" font-family="g_d0_f4" font-size="1px" fill="rgb(43,46,52)">Ibritumomab tiuxetano</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 159.415199 492.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">:</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 481.8382) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.945 1.167 1.611 2.055 2.277 2.666 3.11 3.499 3.721 4.165 4.609 5.053 5.442 5.664 5.886 6.108 6.33 6.774 7.052 7.496 8.163 8.607 8.829 9.273 9.717 9.939 10.495 10.939 11.383 11.827 12.216 12.438 12.882 13.104 13.382 13.826 14.048 14.27 14.659 15.103 15.325 15.769 16.047 16.269 16.713 17.157 17.379 17.768 18.212 18.434 18.878 19.1 19.544 19.933 20.155 20.655 20.877 21.377 21.933 22.377 22.821 23.265 23.487 23.931 24.375 24.597 24.875 25.319 25.708 26.152 26.374 26.818 27.262 27.484 27.928 28.15 28.428 28.872 29.15 29.428 29.872 30.261 30.539 30.983 31.261 31.483 31.927 32.149 32.593 32.815 33.093 33.315 33.593 34.037 34.426 34.648 35.315 35.759 36.203 36.425" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Indicaciones: linfoma no Hodgkin folicular de células B CD20+ en recaída o refractario a rituximab. </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 470.8384) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.9452 1.3892 1.6672 2.1112 2.5002 2.7782 3.2222 3.6112 3.8614 4.3054 4.7494 5.1384 5.5824 5.8604 6.2494 6.6934 7.0824 7.3044 7.5546 7.9986 8.3876 8.6656 9.1096 9.5536 9.7756 10.2196 10.4416 10.6918 11.1358 11.5248 11.9138 12.3578 12.5798 13.0238 13.3018 13.5798 13.8018 14.2458 14.6348 14.8568 15.107 15.329 15.5512 15.9952 16.4392 16.7172 17.1612 17.3832 17.6334 18.0224 18.4664 18.7444 19.1884 19.4104 19.8544 20.2984 20.5204 20.7706 21.0486 21.4926 21.9366 22.3806 22.6586 23.1026 23.4916 23.8806 24.1026 24.5466 24.9906 25.2126 25.4628 25.9068 26.1288 26.5728 27.0168 27.2948 27.7388 28.1828 28.5718 28.7938 29.2378 29.6818 29.9038 30.154 30.598 30.82 31.098 31.542 31.82 32.264 32.653 32.875 33.319 33.763 34.207 34.596 34.8462 35.2902 35.7342 36.1232 36.4012 36.6792 37.1232 37.3452 37.7892 38.0672 38.5112 38.9002 39.1782 39.4002 39.8442 40.2882 40.5102 40.9542 41.3432 41.5652 41.8154 42.0934 42.5374 42.9814 43.3704 43.7594 43.9814 44.4254 44.8694" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Efectos adversos: astenia, escalofríos, ﬁ ebre, cefalea, rubefacción, hipotensión, alteraciones gastrointestinales, reaccione</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 487.176283 470.8384) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.389 0.6392 1.0832 1.3052 1.7492 2.0272 2.4712 2.6932 3.0822 3.5262 3.9152 4.1372" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">s alérgicas, </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 87.87417 459.838599) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.667 0.889 1.333 1.555 1.999 2.388 2.832 3.276 3.554 3.998 4.387 4.609 5.053 5.497 5.719 5.941 6.163 6.607 6.885 7.329 7.718 8.107 8.329 8.773 9.217 9.439 9.828 10.05 10.494 10.938 11.382 11.826 12.048 12.492 12.881 13.103 13.547 13.936 14.158 14.547 14.991 15.38 15.824 16.268 16.712 17.156 17.434 17.656 18.1 18.489" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">mielosupresión, infección y neoplasias secundarias.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 70.8661 437.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(255,127,125)"></svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 76.32 437.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)"> </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 437.802) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.225" x="0 0.415 0.743 1.238 1.677 1.95 2.445 2.829 3.324 4.041 4.536" font-family="g_d0_f4" font-size="1px" fill="rgb(43,46,52)">Trastuzumab</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 124.649998 437.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">:</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 426.8382) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.945 1.167 1.611 2.055 2.277 2.666 3.11 3.499 3.721 4.165 4.609 5.053 5.442 5.664 5.886 6.275 6.719 7.163 7.552 7.996 8.274 8.496 8.94 9.384 9.606 10.273 10.717 11.384 11.828 12.05 12.717 13.161 13.439 13.883 14.272 14.55 14.994 15.383 15.605 15.994 16.438 16.66 17.049 17.493 17.937 18.159 18.548 18.992 19.436 19.714 20.158 20.602 20.991 21.435 21.713 22.157 22.546 22.768 23.212 23.656 23.878 24.322 24.766 24.988 25.544 25.988 26.488 26.932 27.154" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Indicaciones: cáncer de mama metastásico con sobreexpresión de HER2. </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 415.8384) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.9445 1.3885 1.6665 2.1105 2.4995 2.7775 3.2215 3.6105 3.805 4.249 4.693 5.082 5.526 5.804 6.193 6.637 7.026 7.248 7.4425 7.6645 7.887 8.331 8.775 9.053 9.497 9.719 9.9135 10.3575 10.7465 11.1355 11.5795 11.8015 12.2455 12.5235 12.8015 13.0235 13.4675 13.8565 14.0785 14.273 14.717 15.106 15.384 15.828 16.272 16.494 16.938 17.16 17.3545 17.7435 18.1875 18.4655 18.9095 19.1315 19.5755 20.0195 20.2415 20.436 20.658 21.102 21.491 21.935 22.602 23.046 23.268 23.712 23.934 24.1285 24.5725 25.0165 25.4605 25.8495 26.2935 26.7375 27.1265 27.3485 27.543 27.932 28.376 29.043 29.265 29.543 29.987 30.376 30.598 30.7925 31.0705 31.5145 31.9035 32.1255 32.32 32.764 32.986 33.375 33.819 34.263 34.707 34.929 35.1235 35.4015 35.6235 36.0675 36.2895 36.5675 36.7895 37.1785 37.4005 37.595 37.984 38.206 38.65 39.094 39.483 39.705 39.983 40.205 40.594 40.816 41.0105 41.4545 41.6765 42.1205 42.5645 42.8425 43.2865" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Efectos adversos: ﬁ ebre, escalofríos, astenia, cefalea, insomnio, náuseas, vómitos, tos, disnea, rinitis, sinusitis, hipoten</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 472.931101 415.8384) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.389 0.611 1.055 1.499 1.6935 2.0825 2.277 2.721 2.943 3.221 3.665 3.943 4.387 4.776 4.998 5.442" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">sión y alteracio-</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 87.874205 404.838599) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.444 0.888 1.277 1.499 1.888 2.332 2.61 3.054 3.276 3.72 4.109 4.553 4.942 5.164" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">nes cardiacas. </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 70.8661 382.577) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.25" x="0 0.778 1.111 1.5 2.111 2.611 2.889 3.445 4.056 4.389 4.667 5.278 5.834 6.445 7.056 7.334 7.89 8.39 8.668 9.168 9.779" font-family="g_d0_f2" font-size="1px" fill="rgb(64,198,192)">Otros antineoplásicos</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 70.8661 360.838399) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(255,127,125)"></svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 76.32 360.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)"> </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 360.802) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.225" x="0 0.606 1.101 1.429 1.702 2.197 2.581 3.076 3.793 4.01" font-family="g_d0_f4" font-size="1px" fill="rgb(43,46,52)">Bortezomib</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 119.915101 360.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.222" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">: </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 349.8382) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.945 1.167 1.611 2.055 2.277 2.721 2.943 3.387 3.831 4.109 4.331 4.609 5.053 5.442 5.886 6.164 6.553 6.775 7.219 7.441 7.885 8.107 8.551 8.995 9.217 9.439 9.883 10.161 10.605 10.883 11.327 11.771 12.16 12.604 13.271 13.715 13.937 14.381 14.825 15.325" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Inhibidor reversible del proteasoma 26S.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 338.8384) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.945 1.315 1.593 2.037 2.315 2.759 3.426 3.648 4.092 4.536 4.814 5.258 5.48 5.924 6.368 6.59 6.812 7.479 7.701 8.145 8.367 8.811 9.478 9.922 10.144 10.811 11.255 11.477 11.755 11.977 12.421 12.643 13.087 13.309 13.587 14.031 14.309 14.587 15.031 15.42 15.698 16.142 16.42 16.642 17.086 17.308 17.697 18.141 18.808 19.252 19.474 19.752 20.196 20.474 20.918 21.362 21.584 22.028 22.25 22.694 23.138 23.36 23.638 24.082 24.36 24.749 25.193 25.471 25.915 26.137 26.359 26.581 27.025 27.469 27.913" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Tratamiento del mieloma múltiple refractario como terapia de tercera línea.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 327.8386) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.9449 1.5009 1.9449 2.6119 2.8339 3.2779 3.4999 3.8889 4.1669 4.4449 4.8889 5.2779 5.4999 5.9439 6.3879 6.6098 6.8318 7.2758 7.5538 7.8318 8.2758 8.6648 9.1088 9.5528 9.9968 10.3858 10.8298" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Administración intravenosa.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 70.8661 305.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(255,127,125)"></svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 76.32 305.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)"> </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 305.802) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.225" x="0 0.273 0.99 1.485 1.758 1.975 2.47 2.687" font-family="g_d0_f4" font-size="1px" fill="rgb(43,46,52)">Imatinib</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 108.008099 305.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">:</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 294.8382) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.945 1.167 1.611 2.055 2.277 2.721 2.943 3.387 3.831 4.109 4.331 4.775 5.219 5.441 5.663 6.107 6.329 6.607 6.829 7.051 7.329 7.773 8.162 8.384 8.828 9.272 9.55 9.994 10.438 10.66 11.104 11.548 11.937 12.381 12.77 12.992 13.27 13.714 13.936 14.38 14.769 14.991 15.435 15.879 16.323 16.767 17.211 17.6 17.822 18.211 18.655 19.099 19.321 19.765 20.209 20.598 21.042 21.486 21.93 22.374 22.596 23.04 23.429 23.67 23.948 24.392 24.836 25.058 25.28 25.724 26.168 26.39 26.612 27.001 27.279 27.723 28.39 28.834 29.223 29.667 30.334 30.778 31 31.444 31.888 32.332" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Inhibidor de la t irosina-quinasas relacionadas con oncogén bcr-abl del cromosoma Ph1.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 283.8384) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.945 1.315 1.593 2.037 2.315 2.759 3.426 3.648 4.092 4.536 4.814 5.258 5.48 5.924 6.368 6.59 6.812 7.256 7.478 7.7 8.144 8.588 8.977 9.421 10.088 10.31 10.754 10.976 11.643 11.865 12.309 12.531 12.975 13.197 13.641 14.085 14.307 14.696 14.974 15.418 15.862 16.084 16.473 16.917 17.139" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Tratamiento de la leucemia mieloide crónica. </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 272.8386) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.945 1.445 1.889 2.111 2.555 2.999 3.666 3.888 4.332 4.554 4.943 5.221 5.499 5.943 6.165 6.609 7.053 7.331 7.553 7.942 8.164 8.608 8.83 9.274 9.552 9.996 10.218" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Se administra por vía oral.</svg:tspan></svg:text><svg:text transform="matrix(9.5 0 0 9.5 70.8661 239.452) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.25" x="0 0.944 1.5 2.111 2.389 3 3.611 3.889 4.445 4.945 5.223 5.834 6.445 6.723 7.334 7.89 8.168 9.112 9.668 10.279 10.557 11.057 11.613 12.557 13.113 13.724 14.092 14.703 15.203 15.481 15.981 16.259 16.628 17.239 17.628 18.239 18.795 19.073 19.573 20.184" font-family="g_d0_f5" font-size="1px" fill="rgb(255,127,125)">Manipulación de medicamentos citotóxicos</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 70.8661 217.8381) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(255,127,125)"></svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 76.32 217.8381) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.3389 0.8949 1.3389 1.5609 2.0049 2.2829 2.5049 2.8939 3.3379 3.7269" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)"> Objetivos:</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 206.8383) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.945 1.389 1.667 2.111 2.5 2.944 3.388 3.61 3.888 4.11 4.332 4.776 5.165 5.387 5.665 5.887 6.331 6.72 7.164 7.608 7.997 8.219 8.663 9.107 9.385 9.607 9.996 10.44 10.884 11.328 11.717 11.939 12.383 12.827 13.049 13.271 13.715 13.937 14.381 14.77 15.214 15.658 16.047 16.269 16.658 16.88 17.324 17.768 17.99 18.434 18.656 18.878 19.322 19.711 19.933 20.6 21.044 21.488 21.71 22.099 22.543 23.21 23.654 24.098 24.376 24.82 25.209 25.431 25.82 26.042 26.32 26.764 27.042 27.486 27.875 28.097 28.486 28.93 29.319" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Prevenir los riesgos derivados de la exposición a los medicamentos citotóxicos.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 195.8385) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.945 1.501 1.945 2.223 2.667 3.111 3.389 3.611 3.944 4.388 4.666 4.888 5.11 5.554 5.776 6.22 6.609 6.887 7.331 7.609 7.831 8.053 8.275 8.719 9.163 9.607 9.829 10.273 10.717 10.939 11.161 11.605 11.994 12.216 12.883 13.327 13.771 13.993 14.382 14.826 15.493 15.937 16.381 16.659 17.103 17.492 17.714 18.103 18.325 18.603 19.047 19.325 19.769 20.158 20.38 20.769 21.213 21.602 21.824 22.268 22.712 22.934 23.323 23.767 23.989 24.433 24.711 25.155 25.599 26.043 26.321 26.765 27.154 27.376 27.82 28.264" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Garantizar la esterilidad de los medicamentos citotóxicos en su preparación.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 70.8661 173.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0" font-family="g_d0_f3" font-size="1px" fill="rgb(255,127,125)"></svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 76.32 173.838) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.339 0.783 1.061 1.283 1.727 2.116 2.338 2.782 3.004 3.448 3.837 4.059 4.503 4.947 5.169 5.391 5.835 6.057 6.501 6.779 7.223 7.667 8.111 8.389 8.833 9.222 9.444 9.888 10.332 10.554 10.943 11.165 11.609 12.053 12.72 12.942 13.386 13.608 13.997 14.275 14.553 14.997 15.386 15.608 16.052 16.496 16.718 17.162 17.606 17.828 18.217 18.439 18.717 19.161 19.55 19.828 20.272 20.55 20.772 21.161 21.605 21.994" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)"> Principios en la preparación y administración de citostáticos:</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.3701 162.8382) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.298 0.9444 1.5204 1.9294 2.3934 2.6914 2.9338 3.3428 3.5848 4.0488 4.7358 5.1998 5.4978 5.9618 6.2042 6.6682 7.1322 7.5962 8.0602 8.3582 8.8222 9.2312 9.4736 9.9376 10.4016 10.644 10.886 11.35 11.648 12.112 12.521 12.7634 13.2274 13.4698 13.9338 14.4538 14.9738 15.2162 15.4582 15.9222 16.2202 16.6842 17.0932 17.3352 17.7992 18.0416 18.2836 18.7476 19.1566 19.6206 20.0846 20.5486 20.791 21.255 21.719 21.9614 22.6484 23.1124 23.5764 24.0404 24.4494 24.6914 24.9334 25.1758 25.6398 26.1038 26.4018 26.8658 27.1078 27.3502 27.8142 28.2782 28.5762 29.0402 29.4492 29.6916 30.1556 30.4536 30.9176 31.2156 31.6796 32.0886 32.3866 32.8506 33.1486 33.6126 34.0216 34.2636 34.506 35.193 35.657 36.066 36.475 36.939 37.237 37.479 37.721 37.963 38.427 38.6694 39.0784 39.3208 39.7848 40.2488 40.5468 40.8448 41.3088 41.5508 41.7932 42.2572 42.7212 43.0192 43.4832 43.7256 44.1896 44.5986 44.8406 45.1386 45.6026 45.9006 46.143 46.552 47.016 47.48 47.778 48.242" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Usar siempre guantes de látex o PVC (previo lavado de manos), bata, gafas protectoras, mascarilla y gorro, para evitar contam</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 519.730215 162.8382) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.242" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">i-</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 87.874205 151.838399) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.464 0.928 1.337 1.579 2.043 2.507" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">nación.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.370105 140.838599) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.9447 1.5557 1.9997 2.2234 2.6674 3.1114 3.5554 3.9994 4.4434 4.6671 5.3341 5.7781 6.2221 6.4441 6.8881 7.3321 7.5541 7.9981 8.2761 8.4998 8.8888 9.1108 9.3888 9.8328 10.2218 10.4998 10.9438 11.2218 11.4438 11.8328 12.2768 12.6658 12.8895 13.1115 13.5555 13.9445 14.1682 14.8352 15.2792 15.5012 15.9452 16.2232 16.6672 17.0562 17.2799 17.7239 18.3909 18.8349 19.2789 19.5569 20.0009 20.3339 20.7779 21.2219 21.6659 22.0549 22.2786 22.7226 22.9463 23.3353 23.7793 24.2233 24.447 24.891 25.113 25.502 25.78 26.224 26.502 26.724 27.168 27.557 27.7807 28.2247 28.5027 28.9467 29.3357 29.5577 30.0017 30.3907 30.6144 31.0584 31.5024 31.7261 32.1701 32.6141 33.0581 33.3361 33.6141 34.0581 34.4471 34.6691 34.8928 35.3368 35.5588 35.7825 36.0605 36.5045 37.1715 37.6155 38.0595 38.4485 38.8925 39.1162 39.3382 39.7822 40.1712 40.3949 40.8389 41.2829 41.5609 41.9499 42.3939 42.8379 43.2819 43.6709 43.8946 44.3386 44.7826 45.2266 45.4503 45.8943 46.3383 46.7273 47.1713" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- No deben manipular citostáticos las mujeres embarazadas o con historias previas de abortos, ni tampoco las personas que hayan</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 507.89791 140.838599) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.2237 0.502 0.9463 1.3356 1.5579" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)"> reci-</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 87.874209 129.838799) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.444 0.666 1.11 1.554 1.776 2.054 2.332 2.776 3.054 3.498 4.165 4.387 4.831 5.275 5.553 5.997 6.386 6.608 7.052 7.33 7.774 8.163 8.385 8.829 9.218 9.44 9.884 10.106 10.55 10.994 11.438 11.66 12.104 12.548 12.937 13.381 13.825 14.047 14.491 14.88 15.158 15.602 16.046 16.49 16.712 17.156 17.545 17.989 18.433 18.877 19.266 19.544 19.988 20.377 20.599 21.043 21.265 21.543 21.987 22.431 22.653 23.097 23.486 23.708 24.152 24.596 25.04 25.429 25.651 25.873 26.317 26.761 26.983 27.316 27.76 28.204 28.482 28.926 29.315" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">bido tratamientos previos o que hayan estado expuestas a radiaciones ionizantes.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.37011 118.838998) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.9452 1.4452 1.8892 2.5562 3.0002 3.2782 3.7222 4.1662 4.6102 4.8882 5.1284 5.5724 5.7944 6.0346 6.4786 6.9226 7.5896 8.0336 8.3116 8.7556 8.9958 9.4398 9.8838 10.1058 10.346 10.79 11.234 11.512 11.956 12.234 12.901 13.345 13.567 13.8072 14.2512 14.4732 14.7134 14.9914 15.4354 15.7134 16.3804 16.8244 17.2134 17.6574 17.8976 18.3416 18.7856 19.2296 19.4698 19.8588 20.3028 20.543 20.932 21.376 21.6162 22.0602 22.3004 22.7444 23.1884 23.8554 24.0774 24.5214 24.7434 25.1324 25.4104 25.6884 26.1324 26.3404 26.5624 26.8026 27.0246 27.4686 27.7088 28.1528 28.5968 28.9858 29.2078 29.5968 29.8188 30.059 30.503 30.725 30.9652 31.2432 31.4652 31.9092 32.5762 33.0202 33.4642 33.7044 34.1484 34.5924 34.8326 35.2766 35.7206 35.9986 36.2766 36.7206 37.1096 37.3316 37.7756 38.2196 38.4416 38.6818 38.9038 39.3478 39.588 39.866 40.31 40.699 41.143 41.587 41.8272 42.2712 42.7152 42.9554 43.3444 43.7884 44.2324 44.6764 45.0654 45.2874 45.7314 46.1754 46.6194" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Comprobar el nombre del enfermo, el fármaco que se va a administrar, la dosis, el tiempo de perfusión, la fecha de caducidad </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 501.095696 118.838998) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.389 0.6292 0.8512 1.2952 1.5354 1.9244 2.1464 2.5904" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">y la vía </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 87.873287 107.839198) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.444 0.888 1.11 1.554 1.998 2.665 2.887 3.331 3.553 3.942 4.22 4.498 4.942 5.331 5.553 5.997 6.441" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">de administración.</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.369188 96.839398) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.288 0.9446 1.4546 1.6866 2.1406 2.5396 2.8932 3.3472 3.8012 4.1548 4.6088 5.0628 5.7398 5.9718 6.4258 6.6578 7.0568 7.3448 7.6328 8.0868 8.4858 8.7178 9.1718 9.6258 9.8578 10.2114 10.6654 11.1194 11.5734 12.0274 12.4264 12.8804 13.3344 13.7884 14.1874 14.6414 14.8734 15.227 15.681 15.969 16.423 16.655 16.887 17.2406 17.4726 17.9266 18.2146 18.5026 18.9566 19.6336 20.0876 20.4866 20.8856 21.3396 21.5716 22.0256 22.2436 22.4756 22.8292 23.1172 23.5712 24.0252 24.2572 24.6562 25.1102 25.4638 25.9178 26.2714 26.5594 27.0134 27.4674 27.6994 28.1534 28.6074 29.0614 29.2934 29.647 29.879 30.111 30.565 30.853 31.141 31.595 31.883 32.337 32.736 33.19 33.422 33.654 34.0076 34.2396 34.6936 34.9816 35.2696 35.7236 36.1776 36.6316 36.9196 37.1516 37.4396 37.8936 38.3476 38.8016 39.2556 39.4876 39.7196 40.0732 40.3052 40.7592 41.0472 41.3352 41.7892 42.1882 42.6422 43.0412 43.2732 43.6722 44.1262 44.3582 44.5902 44.9438 45.1758 45.6298 45.9178 46.2058 46.6598" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Vías de administración: endovenosa, oral, intramuscular, tópica o regional (intratecal, intraperitoneal, intravesical, intrap</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 503.385286 96.839398) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.232 0.686 1.14 1.428 1.882 2.114 2.336" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">leural, </svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 87.873292 85.839597) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.232 0.686 0.974 1.262 1.716 2.17 2.458 2.746 3.2 3.488 3.72 4.174 4.406 4.638" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">intraarterial).</svg:tspan></svg:text><svg:text transform="matrix(9 0 0 9 79.369192 74.839797) scale(1, -1)" xml:space="preserve"><svg:tspan y="-0.221" x="0 0.278 0.945 1.445 1.889 2.556 3 3.222 3.444 3.833 4.277 4.666 4.888 5.332 5.776 5.998 6.442 6.886 7.108 7.33 7.774 7.996 8.44 8.884 9.551 9.773 10.217 10.439 10.828 11.106 11.384 11.828 12.217 12.439 12.883 13.327 13.549 13.993 14.437 14.659 15.048 15.27 15.548 15.992 16.381 16.659 17.103 17.381 17.603 17.992 18.436 18.825 19.047 19.491 19.935 20.213 20.435 20.824 21.046 21.49 21.712 22.156 22.6 23.044 23.488 23.877 24.321 24.765 25.209 25.598 26.042 26.264 26.486 26.93 27.319 27.597 27.875 28.319 28.708 29.152 29.541 29.985 30.374 30.596 31.04 31.484 31.706" font-family="g_d0_f3" font-size="1px" fill="rgb(43,46,52)">- Complicación de la administración de citostáticos por vía endovenosa: extravasación. </svg:tspan></svg:text></svg:g></svg:g></svg:g></svg:svg>